Head & Neck Cancer (RTOG 0920): Postoperative Radiation Therapy for Locally Advanced Resected
A Randomized Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer
Head and Neck
T1 N1-2, T2-3 N0-2 M0. Hypopharynx primary and distant metastasis not eligible. Gross total resection of primary tumor with curative intent. Must have one or more of the following "intermediate" risk factors -- perineural invasion; lymphovascular invasion; single lymph node > 3 cm or >/= 2 lymph nodes (all < 6 cm) [no extracapsular extension]; close margin(s) of resection (within 5 mm of surgical margins); T3 or microscopic T4a primary tumor; T2 oral cavity cancer with > 5mm depth invasion. Dental evaluation. Positive margins, nodal extracapsular extension and/or gross residual disease after surgery are not eligible.